8H·

$HIMS (+0,07 %)


🚨 FDA keeps Tirzepatide on the shortage list. Also cites "steady and growing" demand from compounders like $HIMS as proof of shortage.


This bodes well for keeping Semaglutide on the shortage list aswell.


FDA to update on Dec 19, 2024.

6
Únase a la conversación